

## CASE REPORT

# Pulmonary Lymphangiomyomatosis in Bourneville's Tuberos Sclerosis: Case Report

Asmae El Ismaili\*, Mouni A Serraj, Bouchra Amara, MC Benjelloun

## ABSTRACT

Lymphangiomyomatosis is a rare disease characterized by a proliferation of abnormal smooth muscle cells responsible for infiltration with the destruction of tissue architecture and genesis of cystic lung and lymphatic lesions. In addition to lung damage, Bourneville's tuberous sclerosis (BTS) also affects the skin, brain, retina, kidneys, and, less frequently, the heart and bone.

We report the case of a young patient with bilateral pneumothorax revealing pulmonary lymphangiomyomatosis in the context of Bourneville's tuberous sclerosis.

**Keywords:** Bilateral pneumothorax, Bourneville's Tuberosclerosis, Pulmonary lymphangiomyomatosis, Subependymal Cerebral nodules.

*International Journal of Health and Biological Sciences*, (2020); DOI: 10.46682/ijhbs.3.2.2

## INTRODUCTION

There is a genetic relationship with Bourneville's tuberous sclerosis (BTS) and lymph angiomyomatosis, including the participation of the tuberous sclerosis complex 2 (TSC2) gene, that's why clinicians need to be conscious of the association and to make STB assessment in the face of any suspicion of lymph angiomyomatosis (namely bilateral pneumothorax)

## Observation

She is a patient aged 25 yo, mentally-retarded, followed for an undocumented kidney problem for the last 4 years.

Since 4 months, she reports dyspnea of effort with aggravation of the bilateral-lumbar pain.

The symptomatology increased one-month ago by a dyspnea of rest with a dry cough without chest pain or hemoptysis, which prompted her to go to the emergency, the clinical examination found a polygenic patient at 32 c/min SaO<sub>2</sub> at 79%, intercostal draught with a bilateral air epileptic syndrome.

A chest X-ray was taken, showing a bilateral pneumothorax of great abundance on the right and a partial pneumothorax on the left.

The patient was drained on both sides with good evolution.

Elsewhere, skin examination found fibrous plaques on the forehead, papular lesions on both cheeks and on the wings of the nose, acromic plaques on the external surface of the left thigh, 2-hypochromic macules on the left thigh, and a small number of fibrous plaques on the right thigh.

The abdominal examination found bilateral lumbar tenderness and neurological examination is without peculiarities

cranial and thoracoabdominal scan (done after an accidental fall of the left drain) objectified a bilateral cystic pulmonary lesion and a right pneumothorax (Figure 1).

in addition to the chest abnormalities, the scan showed subependymal cerebral nodules (Figure 2) and renal mass on both sides (angiomyolipoma) (Figure 3).

Department of pneumology, University Hospital Hassan II, Fes, Morocco

Faculty of Medicine and Pharmacy, University Sidi Mohamed Ben Abdellah, Fes, Morocco

**Corresponding Author:** Asmae El Ismaili, M.D., Department of pneumology, University Hospital Hassan II, Fes, Morocco, Email: asmaeelismaili88@gmail.com

**How to cite this article:** El Ismaili A, Mouniaserraj, Bouchraamara, Benjelloun MC. Pulmonary Lymphangiomyomatosis in Bourneville's Tuberos Sclerosis: Case Report. *International Journal of Health and Biological Sciences* 2020; 3(2):6-8


**Source of support:** Nil

**Conflict of interest:** None

**Received:** 21/04/2020 **Revised:** 02/05/2020 **Accepted:** 15/05/2020

The diagnosis of Bourneville's tubular sclerosis was retained. in search of other abnormalities, a cardiology consult with cardiac echography ruled out a heart condition as well as an ophthalmological examination.


Surgical pleurodesis was proposed, but the patient was recused by the anesthetist because of the major risk of ventilating pathological lungs.



**Figure 1:** CT scan showing bilateral cystic pulmonary lesion and a right pneumothorax in the context of tuberous bourneville sclerosis.



**Figure 2:** Cranial scan showing a subependymal cerebral nodule in the context of tuberous bourneville sclerosis.



**Figure 3:** Abdominal scan showing renal angiomyolipoma in the context of tuberous bourneville sclerosis.

The evolution was marked by the return of the lung to the wall, mTOR inhibitors were prescribed to the patient rather discharge from hospital.

**DISCUSSION**

Lymphangiomyomatosis a rare disease in young women, in a period of genital activity, the average age of diagnosis varies between 30 and 45 years.<sup>[1]</sup>

During the Bourneville's tubular sclerosis, the physio-pathology implies the mutation of the tumor suppressor genes TSC1 and TSC2.

Pulmonary lymph angiomyomatosis is often discovered in the course of a pneumothorax. The Suspicion of tuberous

bourneville sclerosis requires a complete systematic review in search of other systemic disorders, the diagnosis of BTS is based on clinical, radiological, and some times genetic criteria (Table 1).<sup>[2]</sup>

It is the identification of the two genes responsible for the disease, which, by making it possible to understand how these tumors were forming, paved the way for treatment medical. A crucial discovery was that protein seconded by these two genes form a complex that physiologically inhibits the mammalian target of rapamycin (mTOR) signaling pathway (for mammalian Target Of Rapamycin), which has a role central to the physiological control of proliferation cell phone. It appeared that when one of these proteins is

**Table 1:** Diagnostic criteria of Bourneville's tubular sclerosis (Northrup *et al.*)

<i>Genetic diagnostic criteria</i>	<i>Clinical diagnostic criteria</i>
identification of a pathogenic mutation in the TSC1 or TSC2 gene in DNA extract edfrom normal tissues is sufficient to make a definit ediagnosis of Bourneville's tubular sclerosis In 10 to 25% of people with Bourneville's tubular sclerosis, conventional genetic tests do not reveal a mutation. However, a normal result does not rule out the diagnosis.	Major criteria : 1- Hypomelanotic spots (>3), minimum 5mm in diameter 2- Angiofibromas (>3) or cephalic fibrous plaques. 3- Nailfibroids 4- Grief Skin Plates 5- Multiple retinal hamartomas 6- Cortical dysplasia (cortical tubers or lines of radial migration in the white matter) 7- Subependymal Nodules 8- Subependymalgiantcelltumor 9- Cardiacrhabdomyoma 10- Lymphangioliomyomatosis * 11- Angiomyolipomas * Minorcriteria : 1- "Confetti" skin lesions 2- Wells in dental enamel (>3) 3- Intra-oral fibroids (>2) 4- Achromicroretinal spots 5- Multiple renal cysts 6- Non-renal Hamartomes

Definite diagnosis: 2 major criteria or 1 major and 2 minor criteria

Possible diagnosis: 1 major criteria or more than 2 minor criteria

A combination of the two major clinical criteria, which are Lymphangioliomyomatosis and Angiomyolipomas, without other features of tuberous bourneville sclerosis, is not considered for definitive diagnosis.

deficient due to a mutation of TSC1 or TSC2, the excessive activation of this signaling channel mTOR conducts, in tissues where a second somatic mutation, to the tumor proliferation that goes constitute the hamartoma. Hence the use of mTOR inhibitors (already used in organ transplantation): sirolimus or rapamycin (Rapamune®) or everolimus (Certican®).

The effect of these drugs was first tested in animal models and then in a few patients with large cerebral or renal hamartoma. The result is favorable; clinical trials were conducted in patients with renal manifestations,<sup>[3]</sup> pulmonary,<sup>[3]</sup> and cerebral.<sup>[4]</sup> Results are impressive and consistent: after 6 months of treatment, the size of the tumors in this various organs is reduced by more than 30% in 75% of cases. of patients.<sup>[5]</sup> In two recent clinical trials reported using everolimus 117 patients treated for cerebral astrocytoma (84% under the age of 18 years of age) and 118 treated for renal MLA, a reduction of size of more than 50% of the targeted tumour is obtained, at the After one year, in 35 and 42% of patients, respectively.<sup>[6,7]</sup> At the end of the current follow-up (19-33 months; mean 28 months), the lesions continue to decrease or in any case stabilize. However, these drugs do cause enough often some side effects, including the main are stomatitis and respiratory tract infections.<sup>[8,9]</sup>

Rapamycin has also been tested in topical use. at concentrations ranging from 0.003 to 1% for the treatment of angiofibroma of the face, with results very encouraging both in size and appearance.

## CONCLUSION

Pulmonary lymphangiomyomatosis most often progresses to chronic respiratory failure within a few years or decades. Hormonal therapy has not been shown to be effective in the absence of controlled clinical trials. Lung transplantation is

the last therapeutic resort; rare recurrences of transplant edlungs have been reported.

## REFERENCES

1. Johnson SR. Lymphangiomyomatosis. In Orphan Lung Diseases 2015 (pp. 271-283).
2. Northrup H, Krueger DA. International Tuberous Sclerosis Complex Consensus Group. Tuberous Sclerosis Complex Diagnostic Criteria Update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol* 2013; 49: 243-254.
3. Bissler J, McCormack F, Young L *et al.* Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangiomyomatosis. *N Engl J Med* 2008; 358: 140-151.
4. Krueger DA, Care MM, Holland K, *et al.* Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. *N Engl J Med.* 2010; 363(19):1801-1811.
5. Pirson Y. Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action. *Nephrol Dial Transplant* 2013; 28:1680-1685.
6. Franz DN, Belousova E, Sparagana S *et al.* Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2013; 381: 125-132.
7. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E *et al.* Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2013; 381:817-824.
8. Franz DN, Belousova E, Sparagana S *et al.* Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. *Lancet Oncol* 2014; 15:1513-1520.
9. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E *et al.* Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis: extension of a randomized controlled trial. *Nephrol Dial Transplant* 2015